Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En 48-måneders studie for å evaluere langsiktig effektivitet av Elocta på leddhelse (A-MORE)

18. september 2026 oppdatert av: Swedish Orphan Biovitrum

En 48-måneders, multisenter, observasjonsstudie for å evaluere langsiktig effektivitet av Elocta på leddhelse

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Studietype

Observasjonsmessig

Registrering (Faktiske)

427

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Tallinn, Estland
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estland
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finland
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finland
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Hellas
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Hellas
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Bari, Italia
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italia
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italia
        • Giannina Gaslini Institute
      • Milan, Italia
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italia
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italia
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italia
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Groningen, Nederland
        • University Medical Center Groningen/UMCG
      • Muscat, Oman
        • The Royal Hospital
      • Riyadh, Saudi-Arabia
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Saudi-Arabia
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Saudi-Arabia
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Saudi-Arabia
        • Riyadh Military Hospital (P.S.M.C)
      • Ljubljana, Slovenia
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Spania
        • Sant Johan De Deu
      • Barcelona, Spania
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spania
        • Hospital Vall d'Hebron
      • Cruces, Spania
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Spania
        • Hospital Universitario Donostia
      • Murcia, Spania
        • Hospital Virgen de la Arrixaca
      • Málaga, Spania
        • Hospital Universitario Carlos Haya
      • Navarro, Spania
        • Complejo Hospitalario de Navarra
      • Oviedo, Spania
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Spania
        • Hospital Universitario Son Espases
      • Seville, Spania
        • Hospital Universitario Virgen del Rocío
      • Vigo, Spania
        • Hospital Alvaro Cunqueiro
      • Canterbury, Storbritannia
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Storbritannia
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Bern, Sveits
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Sveits
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Sveits
        • Zentrum für Labormedizin
      • Zurich, Sveits
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Gothenburg, Sverige
        • Hematologimottagning Sahlgrenska
      • Malmö, Sverige
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Brno, Tsjekkia
        • University Hospital Brno
      • Ostrava, Tsjekkia
        • University Hospital Ostrava
      • Prague, Tsjekkia
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Berlin, Tyskland
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Tyskland
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Tyskland
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Tyskland
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Tyskland
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Tyskland
        • Medizinische Hochschule Hannover
      • Hanover, Tyskland
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Tyskland
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Tyskland
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Tyskland
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Beskrivelse

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Andre navn:
  • efmoroctocog alfa
  • VELGE
  • rFVIIIFc

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Joint health: Target joint development
Tidsramme: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Tidsramme: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Tidsramme: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Tidsramme: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Tidsramme: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Tidsramme: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Tidsramme: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Tidsramme: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Tidsramme: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Tidsramme: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Tidsramme: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Tidsramme: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Tidsramme: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Tidsramme: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Tidsramme: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Tidsramme: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsramme: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Tidsramme: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Tidsramme: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Tidsramme: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Tidsramme: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Tidsramme: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Tidsramme: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Tidsramme: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Tidsramme: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Tidsramme: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Tidsramme: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Tidsramme: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Study Physician, Swedish Orphan Biovitrum

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. mars 2020

Primær fullføring (Faktiske)

4. mai 2026

Studiet fullført (Faktiske)

4. mai 2026

Datoer for studieregistrering

Først innsendt

20. februar 2020

Først innsendt som oppfylte QC-kriteriene

2. mars 2020

Først lagt ut (Faktiske)

3. mars 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere